What have we really learned from 'LIBERATE' trial?
LIBERATE trial reports that Tibolone use increases the risk of recurrence in breast cancer patients with vasomotor symptoms. However, there are some uncertainties and weak points in the study. Emerged questions are if interpretation of the results could be extrapolated to all breast cancer patients or there are specific subgroups that could use Tibolone without increasing relapse rate.
1st Department of Ob/Gyn, Athens University Medical School, Athens, Greece. atsigginou@med.uoa.gr
Constantine
C
Dimitrakakis
Alexandra
A
Tsigginou
Dimitris
D
Keramopoulos
Aris
A
Antsaklis
D001943:Breast Neoplasms / Q000150:complications*; D020847:Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019584:Hot Flashes / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008593:Menopause; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D009652:Norpregnenes / Q000009:adverse effects* / Q000627:therapeutic use
D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; C027385:tibolone